TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03093350

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA-specific CTLs
Description: Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc.~Dose schedule:~Day 0: 2 x 10\^7 cells/m2~Day 28: 2 x 10\^7 cells/m2~If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion.
Study: NCT03909204

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LAPEC
Description: Laparoscopic-Assisted Percutaneous Endoscopic Cecostomy: Initially, one to tree-laparoscopy port technique will be used, with hand placement of seroperitoneal sutures for cecal fixation. After than during colonoscopy a cecal position will be visualized and colonic lumen will be insuflated. After than the PEC tube will be introduced into the cecum using the dilators and sheath. Intravenous antibiotics will be given prior to the procedure and will continued parental temporary and later orally after catheter insertion. One weeks later, antegrade colonic enema will start during an out-patient visit including an educational training of the patient to the catheter manipulation. Antegrade enema solution will start at dose of 2ml/kg and will be increased up to 20ml/kg or a maximum dose of 2000 mL daily. Adjuvant of colonic motility stimulants are allowed during follow-up.
Study: NCT00150969

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin K1 (phylloquinone)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pill daily
Study: NCT02091895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: probe-based confocal laser endomicroscopy
Description: After shooting 10% fluorescein sodium in,2.5-5 .0 ml to the object with colorectal disease, the lesion will observed and evaluated with pCLE in real-time and also stored the inspection images.~Then, determines the treatment plan to determine which is applied currently in clinical, Sensitivity, specificity, accuracy, amphoteric predict of pCLE diagnosis, and calculate the agreement of prediction compared to the pathological findings of lesions Based on the inspection image stored, using Delphi approach tests, two or more are discussed, to derive a significant technical phrases.~Check diagnostic agreement of technical phrases which are derived, the matching degree between observers, and developed a new classification method based on this.
Study: NCT00950430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pittsburgh Compound B (C-11 PiB)
Description: Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FDG
Description: Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tau (18-F-AV-1451)
Description: 1. PIB PET scan, Tau PET scan and/or FDG PET scan~2. Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan.
Study: NCT00186069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Magnesium Sulfate 4 gram bolus, followed by a maintenance dose at 2 grams per hour. Rate increases up to 4 grams per hour may be administered per physician discretion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline infusion of 4 gram bolus, followed by 2 grams per hour with rate increases up to 4 grams per hour per physician discretion.
Study: NCT02804243

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal high flow therapy
Description: The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
Study: NCT01630434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Lung
Description: OCS Lung will be used to preserve the donor lungs (Treatment Group).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold flush and storage
Description: Donor lungs will preserved using standard cold flush and storage
Study: NCT04549025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimivalimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimivalimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimivalimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days
Study: NCT02228655

Intervention type: DRUG
Group type: OTHER
Intervention: FMX-8
Study: NCT03376607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBCP programme
Description: The newly-established Home-Based Community Practitioners (HBCPs) programme will enable frontline workers to offer monthly health assessments, disease management and lifestyle advice to diabetic patients, and referral to the district hospitals when needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBCP programme
Description: The newly-established Home-Based Community Practitioners (HBCPs) programme will enable frontline workers to offer monthly health assessments, disease management and lifestyle advice to diabetic patients, and referral to the district hospitals when needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile health application
Description: HBCPs will actively encourage the use of a mobile app by assisting patients to access it (this process is known as facilitated access). The app will enable: (i) the registration of measurements, such as blood glucose and weight; (ii) the registration of concerns and questions in a diary; (iii) the reception of alerts and notifications for the appointments to the health facilities, and; (iv) access to advice on lifestyle improvement and other patient educational material.
Study: NCT02914691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozine 10 mg once daily tablet treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo identical once daily tablet treatment
Study: NCT02905994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Polo-Like Kinase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Standard chemotherapy at dosage and schedule for 7+3 induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Standard chemotherapy at dosage and schedule for 7+3 induction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Bone marrow biopsy assessments scheduled during induction to assess response
Study: NCT01414777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron 8mg IV or placebo will be administered prior to placement of the spinal anesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
Study: NCT00389233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macrogol3350 NA sulphate NACl KCl ascorbic acid NA ascorbate
Description: 1 pack will consist of 2L NRL 994 - 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets for the 2L of 2 sachets (1 x P plus 1 x C) will be dissolved in 1L of water. Each litre will be drunk within 1 hour followed by at least 500ml of any additional clear fluid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol3350 Na sulphate Na bicarbonate NaCl KCl
Description: 1 pack will consist of 4L PEG + E - contains 4 sachets for the 4L of PEG + E/P/E. Each sachet will be dissolved in 1L of water. Each litre will be drunk within 1 hour.
Study: NCT04101708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole, Amoxicillin
Description: high dose dual regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole, Amoxicillin,Clarithromycin and Bismuth subcitrate
Description: half-dose clarithromycin-containing bismuth quadruple regimen
Study: NCT00711529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. surveys. The therapist will be prohibited from asking subjects about clinical responses to the hypnosis sessions. The patients will also be instructed on self-hypnosis techniques to be used at home.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin
Description: Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily). This dose has been shown to be more effective than 300mg daily. Larger doses have not been evaluated in this population, and may be associated with a more significant side-effect profile. The prescription for gabapentin will be provided at the patient's enrollment appointment. The patients will take gabapentin as prescribed daily for the study-enrollment period, which is 8 weeks.
Study: NCT00696761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfuzosin
Description: 10mg, once daily, 12months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfuzosin
Description: 10mg, once daily, 12months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfuzosin
Description: 10mg, once daily, 12months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfuzosin
Description: 10mg, once daily, 12months
Study: NCT01918553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical parameters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual acuity exams

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: retinophotography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SD-OCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra ocular Pressure (IOP)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: retinal imaging (OPTOMAP)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: axial length (IOL master)
Study: NCT02083874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Study: NCT02225496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery (TORS)
Description: Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Barium Swallow (MBS)
Description: MBS performed at baseline and 1 - 4 weeks after surgery, and at 6 months, 12 months and 24 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires about speech and swallowing function completed at baseline, 1 - 4 weeks after surgery, and at 6 months, 12 months, and at 24 months.
Study: NCT02092974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tDCS

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Citalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham-tDCS + placebo
Study: NCT02372188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffein + homoeriodictyol sodium salt

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: homoeriodictyol sodium salt
Study: NCT02928614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg (Saxenda)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide 3 mg placebo
Study: NCT02868593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharyngeal swab
Study: NCT04004988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study: NCT03216057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid 3 grams per day
Description: Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 gr of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega RX Dr.Sears Zone labs Inc.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo Each capsule contains 600 mg of soybean oil. We allocated five capusles per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
Study: NCT01026454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir
Description: acyclovir 400 mg orally, twice daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir
Description: valacyclovir 1.5 g orally, twice daily, for 12 weeks
Study: NCT04004988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled syringe (PFS)
Description: PFS used to administer tirzepatide
Study: NCT02580955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LEGFLOW DCB
Study: NCT00323297

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bosentan
Description: Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
Study: NCT03613753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan plus lobaplatin
Description: irinotecan plus lobaplatin chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: irinotecan chemotherapy alone
Study: NCT04098965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pysiotherapy techniques
Description: manual therapy techniques, postural re-education and muscle strengthening

Intervention type: OTHER
Group type: OTHER
Intervention: physician treatment
Description: hygienic-dietary recommendations, Kegel exercises and pain relievers
Study: NCT02404207

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soybean oil
Description: Participants will be fed soybean oil as part of a controlled (typical American) diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-oleic soybean oil
Description: Participants will be fed high-oleic soybean oil as part of a controlled (typical American) diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-oleic soybean oil + fully hydrogenated soybean oil
Description: Participants will be fed a blend of high-oleic soybean oil and fully hydrogenated soybean oil as part of a controlled (typical American) diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palm olein + palm stearin
Description: Participants will be fed a blend of palm olein + palm stearin as part of a controlled (typical American) diet.
Study: NCT03586687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Ultrasound guided glenohumeral shoulder joint injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Ultrasound guided glenohumeral shoulder joint injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Ultrasound guided glenohumeral shoulder joint injection
Study: NCT02854293

Intervention type: OTHER
Intervention: Booklet-Question List
Description: Booklet-Question List (BQL) proposed in palliative cares, divided into 8 chapters, given to the patient before the first palliative care consultation.~Providing a list of questions to patients and their families without any obligations allows individual adaptation of information; patients or families who are afraid of asking these questions can take advantage of this opportunity, while respecting the need to avoid these subjects for other patients
Study: NCT04004988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-injector (AI)
Description: AI used to administer tirzepatide
Study: NCT00934804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galilei dual Scheimpflug analyzer
Description: The Galilei dual Scheimpflug analyzer is a non-invasive, diagnostic system that combines dual rotating Scheimpflug camera measurements and Placido optical system for corneal topography and 3D analysis of the anterior eye segment.
Study: NCT01769066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Gefitinib With Pemetrexed/Platinum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/Platinum
Study: NCT01703234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: ramipril 10 mg/day during 3 months
Study: NCT04382040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ArtemiC
Description: Treatment will be sprayed orally twice a day for the first 2 days in the treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
Study: NCT01219881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: 5.4 to 7.4% desflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 1.4 to 2.5% Sevoflurane
Study: NCT02982746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gPCC (Gothenburg Person Centred Care)
Study: NCT01544257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment
Description: Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Usual care
Description: Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
Study: NCT05199103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit anti-thymocyte globulin
Description: 0.8 - 1.0 mg/kg of rATG (cumulative dose of 150-200 mg given intravenously in two or three divided doses, 24 hours apart) after premedication with methylprednisolone i.v. (in total dose of 375 mg), 1 mg of antihistaminic agent clemastine and 1000 mg paracetamol i.v.
Study: NCT03739268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer
Description: Sevelamer powder dissolved in water 1,600 mg three times a day for 17 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo powder dissolved in water 1,600 mg three times a day for 17 days
Study: NCT01635153

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein calorie supplement
Description: Fortified porridge with 1062 kcal and 40 gm protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Micronutrient
Description: Dar-vite Multivitamin
Study: NCT01397214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megace F
Description: Megace F oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megace OS
Description: Megace oral suspension
Study: NCT03033095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept ® 50 mg
Description: The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
Study: NCT03674853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wuling Capsule
Description: take Wuling Capsule in experiment group for 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oryzanol
Description: take oryzanol in active comparator group for 2 months
Study: NCT01610011

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycine administration
Description: Glycine will be administered once as a 250 cc lemon-flavored beverage based on each subject's body weight. The drink concentration will be 0.4 g/kg glycine (not to exceed 30 grams). Subjects will have 10 minutes to consume the beverage.